Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Merck KGaA Stops MS Pill Effort as FDA Seeks More Tests

June 22 (Bloomberg) -- Merck KGaA, which lost the race against Novartis AG to introduce the first multiple sclerosis pill, will no longer seek approval for the experimental Cladribine medicine after regulators said the German drugmaker would have to start a new clinical trial program.

The decision will result in an exceptional charge of 20 million euros ($28.8 million) in the second quarter, the Darmstadt, Germany-based company said in an e-mailed statement today.

“Attempting to fulfill the FDA and the EMA requirements would necessitate the initiation of a new clinical trial program which would take several years to complete,” Merck said in the statement. Cladribine’s benefit-risk profile hasn’t changed, it said.

To contact the reporter on this story: Mariajose Vera in Munich Bureau at

To contact the editor responsible for this story: Angela Cullen at

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.